stockrowZai Lab Limited Unsponsored ADR
ZLAB Healthcare Biotechnology
Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024.
- Revenue
- −6.79%
- EPS
- −24.3%
- Free cash flow
- −95.5%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
Follow ZLAB
Alert me
Zai Lab Limited Unsponsored ADR (ZLAB) EBITDA
Zai Lab Limited Unsponsored ADR's EBITDA for fiscal 2025 was −$219.8M, compared with −$273.8M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$253.7M. Over the past ten years it has ranged from −$694.1M (fiscal 2021) to −$16.2M (fiscal 2015); the current reading is higher than 55% of that period. EBITDA has risen for 4 consecutive fiscal years. Zai Lab Limited Unsponsored ADR ranks 537th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$219.8M | — |
| FY2024 | −$273.8M | — |
| FY2023 | −$360.9M | — |
| FY2022 | −$398.7M | — |
| FY2021 | −$694.1M | — |
| FY2020 | −$297.5M | — |
| FY2019 | −$199.7M | — |
| FY2018 | −$140.4M | — |
| FY2017 | −$50.9M | — |
| FY2016 | −$38.3M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$73.8M | — |
| Mar 2026 | −$66.8M | — |
| Dec 2025 | −$66.8M | — |
| Sep 2025 | −$46.3M | — |
| 24 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ADMA ADMA Biologics Inc compare | $232.8M |
| MBX MBX Biosciences, Inc. compare | −$117.7M |
| XNCR Xencor, Inc. compare | −$209.4M |
| PHVS Pharvaris N.V. compare | −$212.2M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$233.2M |
| ZLAB Zai Lab Limited Unsponsored ADR | −$253.7M |
| CLDX Celldex Therapeutics, Inc. compare | −$326.7M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$421.1M |
| RCUS Arcus Biosciences, Inc. compare | −$488.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ZLAB
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement